KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortization of GoodwillAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pacira BioSciences (PCRX) Amortization of Deferred Charges (2023 - 2025)

Pacira BioSciences (PCRX) has 3 years of Amortization of Deferred Charges data on record, last reported at $520000.0 in Q4 2025.

  • For Q4 2025, Amortization of Deferred Charges fell 44.56% year-over-year to $520000.0; the TTM value through Dec 2025 reached $2.8 million, down 11.86%, while the annual FY2025 figure was $2.8 million, 11.86% down from the prior year.
  • Amortization of Deferred Charges reached $520000.0 in Q4 2025 per PCRX's latest filing, down from $626000.0 in the prior quarter.
  • Across five years, Amortization of Deferred Charges topped out at $1.4 million in Q4 2023 and bottomed at $520000.0 in Q4 2025.
  • Average Amortization of Deferred Charges over 3 years is $817500.0, with a median of $801500.0 recorded in 2024.
  • The widest YoY moves for Amortization of Deferred Charges: up 24.08% in 2025, down 44.56% in 2025.
  • A 3-year view of Amortization of Deferred Charges shows it stood at $1.4 million in 2023, then crashed by 34.73% to $938000.0 in 2024, then tumbled by 44.56% to $520000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Amortization of Deferred Charges were $520000.0 in Q4 2025, $626000.0 in Q3 2025, and $849000.0 in Q2 2025.